Your browser doesn't support javascript.
loading
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide.
Works, Melissa; Soni, Neha; Hauskins, Collin; Sierra, Catherine; Baturevych, Alex; Jones, Jon C; Curtis, Wendy; Carlson, Patrick; Johnstone, Timothy G; Kugler, David; Hause, Ronald J; Jiang, Yue; Wimberly, Lindsey; Clouser, Christopher R; Jessup, Heidi K; Sather, Blythe; Salmon, Ruth A; Ports, Michael O.
Afiliación
  • Works M; Juno Therapeutics, A Celgene Company, Seattle, Washington. Melissa.works@junotherapeutics.com.
  • Soni N; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Hauskins C; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Sierra C; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Baturevych A; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Jones JC; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Curtis W; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Carlson P; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Johnstone TG; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Kugler D; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Hause RJ; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Jiang Y; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Wimberly L; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Clouser CR; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Jessup HK; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Sather B; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Salmon RA; Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Ports MO; Juno Therapeutics, A Celgene Company, Seattle, Washington.
Mol Cancer Ther ; 18(12): 2246-2257, 2019 12.
Article en En | MEDLINE | ID: mdl-31395689
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de la Angiogénesis / Receptores Quiméricos de Antígenos / Lenalidomida / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de la Angiogénesis / Receptores Quiméricos de Antígenos / Lenalidomida / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos